InflaRx (NASDAQ: IFRX)
$1.35
(7.1%)
$0.09
Price as of April 19, 2024, 4:00 p.m. ET
InflaRx Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
InflaRx Company Info
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
News & Analysis
Featured Article
Why InflaRx Stock Skyrocketed This Week
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
Keith Noonan | Apr 7, 2023
Featured Article
Why Shares of InflaRx Are Soaring Wednesday
A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.
Jim Halley | Apr 5, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.